Product
DC/myeloma fusions/GM-CSF
1 clinical trial
1 indication
Indication
Multiple MyelomaClinical trial
A Phase II Trial of Vaccination With Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple MyelomaStatus: Terminated, Estimated PCD: 2021-01-31